GP532 / Genome Protection - LARVOL DELTA

Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532 (BioSpace) - "The Investigational New Drug (IND) - enabling preclinical development of GP532 for the treatment of idiopathic pulmonary fibrosis (IPF) is supported in part by a $3M grant recently awarded to the company by the US Department of Defense (DoD) via the Congressionally Directed Medical Research Program (CDMRP) the Peer Reviewed Medical Research Program (PRMRP)."

Financing • Preclinical • Idiopathic Pulmonary Fibrosis